Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739203 · ClinicalTrials.gov registry record · Phase 3
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
A Phase 3 study of Major Depressive Disorder, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 752
- Enrollment target
- 20
- Study locations
NCT03739203 is a Phase 3 study of Major Depressive Disorder that has completed, run by AbbVie. The registered enrollment target is 752 participants, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (101% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT03739203, a Phase 3 study of Major Depressive Disorder, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 752 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to antidepressants alone.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cariprazine
- DRUG Antidepressant Therapy (ADT)
Study Locations (20)
California
- California Pharmaceutical Research Institute /ID# 236731 - Anaheim
- Axiom Research /ID# 236267 - Colton
- Global Clinical Trials /ID# 235059 - Costa Mesa
- Collaborative Neuroscience Research - Orange County /ID# 237637 - Garden Grove
- Behavioral Research Specialists, LLC /ID# 236622 - Glendale
- Sun Valley Research Center /ID# 236560 - Imperial
- North County Clinical Research /ID# 235014 - Oceanside
- Excell Research, Inc /ID# 237717 - Oceanside
- NRC Research Institute /ID# 234632 - Orange
- Anderson Clinical Research /ID# 236624 - Redlands
- Syrentis Clinical Research /ID# 237408 - Santa Ana
- California Neuroscience Research Medical Group, Inc. /ID# 236636 - Sherman Oaks
- Schuster Medical Research Institute /ID# 236445 - Sherman Oaks
- Pacific Clinical Research Management Group /ID# 234378 - Upland
Florida
- Innovative Clinical Research /ID# 235186 - Fort Lauderdale
- Gulfcoast Clinical Research Center /ID# 236280 - Fort Myers
Alabama
- Harmonex /ID# 236936 - Dothan
Arkansas
- Woodland International Research Group /ID# 236349 - Little Rock
Colorado
- MCB Clinical Research Centers /ID# 236927 - Colorado Springs
Connecticut
- CT Clinical Research /ID# 234638 - Cromwell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 752 participants |
| Start Date | 2018-11-10 |
| Est. Completion | 2021-09-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03739203
The ClinicalTrials.gov registry entry for NCT03739203 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 752 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (101% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03739203 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT03739203 about?
NCT03739203 is a clinical study titled "The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone". The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to antidepressants alone.
What is the current status of trial NCT03739203?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 752 participants. The study started on 2018-11-10. Estimated completion is 2021-09-06.
What conditions does trial NCT03739203 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT03739203?
The interventions under investigation include: Placebo (DRUG), Cariprazine (DRUG), Antidepressant Therapy (ADT) (DRUG).
Who is sponsoring clinical trial NCT03739203?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03739203 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.